Cardiogenic shock: Have we really found the magic potion?

European Heart Journal

Volumn 24, Issue 14, 2003, Pages 1279-1281

  Menon, Venu ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITROARGININE METHYL ESTER;

CARDIOGENIC SHOCK; CLINICAL FEATURE; EDITORIAL; HEART OUTPUT; HEMODYNAMICS; HUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REGISTER;

ADULT; AGE FACTORS; AGED; ENZYME INHIBITORS; HUMANS; INTRA-AORTIC BALLOON PUMPING; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS; SHOCK, CARDIOGENIC;

EID: 0042745490     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00263-X     Document Type: Editorial

References (11)

1. Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. New England Journal of Medicine 1999;341:625-34.
2. Hochman JS, Sleeper LA, White HD et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190-2.
3. Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/ AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-30.
4. Webb JG, Sanborn TA, Steeper LA et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. American Heart Journal 2001; 141:964-70.
5. Menon V, White H, LeJemtel T et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? Journal of the American College of Cardiology 2000;36:1071-6.
6. Menon V, Slater JN, White HD et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. American Journal of Medicine 2000;108:374-80.
7. Hochman JS. Cardiogenic Shock Complicating Acute Myocardial Infarction: Expanding the Paradigm. Circulation in press.
8. Cotter G, Katuski E, Blatt A et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000;101:1358-61.
9. Cotter G, Katuski E, Milo O et al. LINCS: L-NAME (a NO Synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003;24:1287-95.
10. Koreny M, Karth GD, Geppert A et al. Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. American Journal of Medicine 2002; 112:115-9.
11. Hasdai D, Holmes DR Jr., Califf RM et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. American Heart Journal 1999;138: 21-31.